Moderator: Julianna Merten, PharmD, BCPS, BCOP, Clinical Pharmacy Specialist, Mayo Clinic, Rochester, MN

Please note: If you are attending this program for BCOP recertification, there are different instructions for claiming CE from those attending only for ACPE credit.


ACPE Credit Only: Instructions for claiming CE will be available in the session room. CE will be provided by the Hematology/Oncology Pharmacy Association (HOPA).


BCOP Recertification: These sessions are part of the professional development program for recertification of Board Certified Oncology Pharmacists (BCOPs), approved by the Board of Pharmaceutical Specialties (BPS). Part 1 will be presented on Tuesday, December 6, 8:00 a.m. – 11:00 a.m. BCOPs must attend all six hours of programming to be eligible to complete the Web-based post-test for oncology recertification credit. Partial credit is not available for recertification, but is available for ACPE credit.


At the session room, you must complete a paper registration form and have the barcode on your name badge scanned both in the morning and afternoon sessions as you enter and exit the session room.


The post-test fee is $45. After the Midyear Clinical Meeting, program participants will receive email instructions to purchase and access the test, as well as claim ACPE credit. The post-test examination must be completed and submitted by December 31, 2011.


2:00 p.m. – 3:00 p.m.
The Heart of the Matter: When Targeted Therapies Cause Off-Target Toxicities
UAN# 0465-9999-11-302-L01-P
1.0 Contact Hour/Application-based
Presenter: Courtney Bickford, PharmD, BCPS, Pharmacy Clinical Specialist, Cardiology, MD Anderson Cancer Center, Houston, TX

Learning Objectives:

Distinguish cardiac toxicities (e.g., heart failure, hypertension, QT prolongation, cardiac ischemia) attributable to targeted cancer therapies.

Summarize the evidence regarding the pathophysiology of cardiotoxicities induced by targeted cancer therapies.

Develop evidence-based plans for preventing, monitoring, and treating cardiovascular adverse reactions associated with targeted cancer therapies.

3:00 p.m. – 4:00 p.m.
Germ Cell Tumors (GCT): Beyond BEP
UAN# 0465-9999-11-403-L01-P
1.0 Contact Hour/Application-based
Presenter: Kellie L. Jones, PharmD,Clinical Associate Professor, Purdue University, Indianapolis, IN

Learning Objectives:

Summarize the current standards of therapy for testicular cancer.

Evaluate the impact of stem cell transplant in the metastatic setting.

Compare different salvage therapies utilized in the management of metastatic testicular cancer based on efficacy and toxicity.

Construct treatment recommendations to manage supportive care issues that testicular cancer patients face during treatment.

Outline long-term toxicities associated with the treatment of testicular cancer.

4:00 p.m. – 5:00 p.m.
Vaccinations in Cancer
UAN# 0465-9999-11-402-L01-P
1.0 Contact Hour/Application-based
Presenter: Tracey Walsh-Chocolaad, PharmD
Learning Objectives:

Differentiate the changes in immune function and immunity that occur in patients undergoing therapy for cancer based on age, disease, and chemotherapy regimen.

Summarize the recommendations for vaccinations in oncology patients based on data and guidelines from the CDC, IDSA, and ASBMT.

Analyze limitations in the current available data and gaps in the current recommendations for vaccination in oncology patients.